losartan has been researched along with Anochlesia in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both acute and chronic administration of enalapril/losartan produced an increase in the duration of haloperidol induced catalepsy at the highest dose (20 mg/kg)." | 1.38 | Co-administration of haloperidol and drugs affecting the angiotensin pathway: effect on the extrapyramidal system. ( Gopalakrishna, HN; Nair, V; Pai, MR; Pemminati, S; Shreyasi, C; Swati, B, 2012) |
| " On chronic administration (once daily for 21 days) losartan failed to block apomorphine-induced hyperlocomotion, but the inhibition of stereotypic response and potentiation of neuroleptic-induced catalepsy remained unaltered." | 1.30 | Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. ( Chopra, K; Kulkarni, SK; Raghavendra, V, 1998) |
| "Neuroleptic-induced catalepsy remains a useful method to study central dopaminergic function in rodents." | 1.29 | Effects of losartan on neuroleptic-induced catalepsy in mice. ( Futuro-Neto, HA; Pires, JG; Silva, SR, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pemminati, S | 1 |
| Swati, B | 1 |
| Shreyasi, C | 1 |
| Gopalakrishna, HN | 1 |
| Nair, V | 1 |
| Pai, MR | 1 |
| Pires, JG | 1 |
| Silva, SR | 1 |
| Futuro-Neto, HA | 1 |
| Raghavendra, V | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 1 |
3 other studies available for losartan and Anochlesia
| Article | Year |
|---|---|
Co-administration of haloperidol and drugs affecting the angiotensin pathway: effect on the extrapyramidal system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antipsyc | 2012 |
Effects of losartan on neuroleptic-induced catalepsy in mice.
Topics: Angiotensin Receptor Antagonists; Animals; Antipsychotic Agents; Biphenyl Compounds; Catalepsy; Imid | 1996 |
Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Apomorphine; Benzazepines; Catalepsy; Dopamine; Dopamine | 1998 |